DÄ internationalArchive4/2008Essential Thrombocythemia – Clinical Significance, Diagnosis and Treatment: Increased Myelofibroses

Correspondence

Essential Thrombocythemia – Clinical Significance, Diagnosis and Treatment: Increased Myelofibroses

Dtsch Arztebl Int 2008; 105(4): 71. DOI: 10.3238/arztebl.2008.0071a

Andreas, U

LNSLNS I would like to make the following comments on the outstanding review article of Prof. Grieshammer et al.: to my knowledge, a bone marrow biopsy is not absolutely necessary to diagnose essential thrombocythemia (diagnosis by exclusion sufficient). Moreover, the positive detection of JAK2V617F mutation in half of the patients would rule out reactive thrombocytosis. In the article, I can find no reference to the fact that in a study of Harrison an increased number of myelofibrosis cases occurred after anagrelide therapy. Finally, one question: how can it be explained that the risk of thromboembolism is not increased in secondary thrombocytoses especially since it is still accepted practice to give aspirin in these cases?
DOI: 10.3238/arztebl.2008.0071a

Dr. med. Udo Andreas
Neusser Str. 117
41065 Mönchengladbach, Germany

Info

Specialities